With the recent, highly publicized incidents of identity theft, ransomware and malware attacks directed at healthcare facilities, the medical device community is on high-security alert.
Scientists have created a hair-thin implant that can drip medications deep into the brain by remote control and with pinpoint precision.
Chilmark Vice President Kenneth Kleinberg said that hospitals are deploying AI, image recognition, natural language processing, predictive analytics - and they’re doing so quickly.
A study using epilepsy patients undergoing surgery has given neuroscientists an opportunity to track in unprecedented detail the movement of a thought through the human brain, all the way from inspiration to response.
Remote patient monitoring company LindaCare announced on Friday that they landed $8.6 million (€7 million) in Series B funding with participation by Philips, PMV, Capricorn ICT Arkiv, and Connecticut Innovations.
A team of South Korean researchers is the latest to tout a smart, glucose-sensing contact lens. In a research article published today in Science Advances, the team described soft lenses carrying a tiny LED light that automatically turns off in the event of high glucose levels, as well as their efforts to test the lens in vivo.
Scientists from the University of Alberta have unveiled ProjectDR, technology that uses augmented reality (AR) to display medical images such as CT and MRI scans directly onto a patient’s body.
AstraZeneca AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy.
Tmunity Therapeutics is looking to bring better and safer T-cell therapies for both solid tumors and blood cancers and has scored a $100 million series A to propel it on its journey
Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the U.S.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.